SGLT2 inhibition to address the unmet needs in diabetic nephropathy

Diabetes Metab Res Rev. 2019 Oct;35(7):e3171. doi: 10.1002/dmrr.3171. Epub 2019 May 9.


Current treatment of diabetic nephropathy is effective; however, substantial gaps in care still remain and new therapies are urgently needed to reduce the global burden of the complication. Desirable properties of an "ideal" new drug should include primary prevention of microalbuminuria, additive/synergistic anti-proteinuric effect in combination therapy with renin angiotensin system blockers, reduction of chronic kidney disease progression to lower the risk of end-stage renal disease, and cardiovascular protection. Growing evidence suggests that sodium-glucose cotransporter 2 inhibitors (SGLT2i) may fulfil many of these criteria and represent novel tools to cover the unmet needs in diabetic nephropathy care. However, the underlying mechanisms of SGLT2i renal benefits are still poorly understood and promising results from cardiovascular outcome trials with SGLT2i need confirmation in dedicated renal outcome trials.

Keywords: GFR; SGLT2; albuminuria; diabetic nephropathy; experimental diabetes.

Publication types

  • Review

MeSH terms

  • Diabetic Nephropathies / drug therapy*
  • Diabetic Nephropathies / pathology
  • Humans
  • Needs Assessment*
  • Prognosis
  • Sodium-Glucose Transporter 2 Inhibitors / therapeutic use*


  • Sodium-Glucose Transporter 2 Inhibitors